Recombinant follicle-stimulating hormone (follitropin beta, Puregon) yields higher pregnancy rates in in vitro fertilization than urinary gonadotropins
- 31 July 1997
- journal article
- clinical trial
- Published by Elsevier in Fertility and Sterility
- Vol. 68 (1), 138-142
- https://doi.org/10.1016/s0015-0282(97)81490-2
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- The coming of wondersFertility and Sterility, 1997
- Recombinat hormones: Molecular biology and biochemistry of human recombinant follicle stimulating hormone (Puregon®)Molecular Human Reproduction, 1996
- Recombinant follicle stimulating hormone (rFSH; Puregon) in assisted reproduction: More oocytes, more pregnancies. Results from five comparative studiesHuman Reproduction Update, 1996
- Meta-analysis: A method for synthesizing research*Clinical Pharmacology & Therapeutics, 1995
- A prospective, randomized, assessor-blind, multicentre study comparing recombinant and urinary follicle stimulating hormone (Puregon versus Metrodin) in in-vitro fertilizationHuman Reproduction, 1995
- Hormonal Regulation of Meiotic Maturation in the Hamster Oocyte Involves a Cytoskeleton-Mediated Process1Biology of Reproduction, 1994
- Female infertility: causes and treatmentThe Lancet, 1994
- Relationship between embryo morphology and implantation rate after in vitro fertilization treatment in conception cyclesFertility and Sterility, 1993
- The routine use of gonadotropin-releasing hormone agonists prior to in vitro fertilization and gamete intrafallopian transfer: a meta-analysis of randomized controlled trialsFertility and Sterility, 1992
- A general parametric approach to the meta‐analysis of randomized clinical trialsStatistics in Medicine, 1991